Eli Lilly to Make Bebtelovimab Commercially Available
Eli Lilly said it will make its COVID-19 drug bebtelovimab commercially available to U.S. states and territories, hospitals and other providers later this month.
The FDA authorized the monoclonal antibody for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients aged 12 years and older and weighing at least 88 pounds who are at high risk of developing severe COVID-19 and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.
Laboratory testing has shown that bebtelovimab, which works by binding to the spike protein of the SARS-CoV-2 virus that causes COVID-19 infection, is effective against the Omicron variant.
Lilly said the drug will be available in the week of Aug.15, before the anticipated depletion of the U.S. government’s currently available supply.